San Diego, CA, United States of America

Lorraine Sullivan

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 94(Granted Patents)


Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Celebrating the Innovations of Lorraine Sullivan: A Pioneer in Modified Relaxin Polypeptides

Introduction: Lorraine Sullivan, an esteemed inventor based in San Diego, CA, has made significant contributions to the field of biochemistry through her innovative work in modified relaxin polypeptides. With a remarkable portfolio of 11 patents, Lorraine stands out as a prominent figure in her industry, demonstrating the impact of her research on medical treatments and therapies.

Latest Patents: Lorraine's latest patents showcase her groundbreaking advancements in biopharmaceuticals. One of her patents focuses on modified relaxin polypeptides and their diverse applications. These polypeptides feature specific amino acid substitutions, potentially linked to a water-soluble polymer, such as polyethylene glycol. This innovative approach holds promise for treating diseases, including heart failure. Furthermore, she has developed nucleic acids encoding these modified relaxin polypeptides, which are critical for advancing applications in medicine.

Career Highlights: Lorraine has established a successful career as a leading inventor in the pharmaceutical arena. Currently, she is associated with Ambrx, Inc., where she continues to push the envelope of medical science through her research and inventions. Her extensive experience and insights have contributed to numerous breakthroughs in drug development and therapeutic applications.

Collaborations: Lorraine Sullivan's journey has been greatly enriched by her collaborations with talented professionals, including Vadim Kraynov and Nick Knudsen. Working alongside these esteemed colleagues has fostered a dynamic exchange of ideas and expertise, further amplifying the impact of their collective research in the field.

Conclusion: Lorraine Sullivan embodies the spirit of innovation, demonstrating a relentless pursuit of knowledge and advancement within the biopharmaceutical industry. Her contributions to the development of modified relaxin polypeptides not only reflect her exceptional skills as an inventor but also present promising solutions for significant health challenges. The ongoing work of Lorraine and her collaborators is set to leave a lasting mark on medical science and the treatment of disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…